Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss.
Mohammad AH, Assadian S, Couture F, Lefebvre KJ, El-Assaad W, Barrès V, Ouellet V, Boulay PL, Yang J, Latour M, Furic L, Muller W, Sonenberg N, Mes-Masson AM, Saad F, Day R, Teodoro JG. Mohammad AH, et al. Among authors: muller w. Oncotarget. 2019 Aug 13;10(48):4923-4936. doi: 10.18632/oncotarget.27075. eCollection 2019 Aug 13. Oncotarget. 2019. PMID: 31452834 Free PMC article.
Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression.
Boulay PL, Mitchell L, Turpin J, Huot-Marchand JÉ, Lavoie C, Sanguin-Gendreau V, Jones L, Mitra S, Livingstone JM, Campbell S, Hallett M, Mills GB, Park M, Chodosh L, Strathdee D, Norman JC, Muller WJ. Boulay PL, et al. Cancer Res. 2016 May 1;76(9):2662-74. doi: 10.1158/0008-5472.CAN-15-2782. Epub 2016 Mar 1. Cancer Res. 2016. PMID: 26933086 Free PMC article.
Elevated V-ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer.
Mohammad AH, Kim SH, Bertos N, El-Assaad W, Nandi I, Smith H, Yang J, Chen OJ, Gamache I, Rao T, Gagnon B, Gruosso T, Tremblay ML, Sonenberg N, Guiot MC, Muller W, Park M, Teodoro JG. Mohammad AH, et al. Among authors: muller w. Mol Cancer Res. 2020 Oct;18(10):1477-1490. doi: 10.1158/1541-7786.MCR-20-0088. Epub 2020 Jun 25. Mol Cancer Res. 2020. PMID: 32587106 Free article.
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.
Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, Denardo D, Coussens LM, Brennan DJ, Gallagher WM, Park M, Pawson T, Hallett M, Muller WJ. Ursini-Siegel J, et al. Cancer Res. 2010 Oct 15;70(20):7776-87. doi: 10.1158/0008-5472.CAN-10-2229. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20924104 Free PMC article.
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. Knight JF, et al. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18. Proc Natl Acad Sci U S A. 2013. PMID: 23509284 Free PMC article.
4,862 results